Addressing a Global Health Priority

Obesity is one of the fastest-growing global health challenges, affecting more than 1 billion people worldwide, including around 890 million adults. It is a leading driver of chronic diseases such as cardiovascular disease, type 2 diabetes, and certain cancers. With the anti-obesity drug market projected to surpass USD 100 billion by 2030, demand for innovative therapies is accelerating, particularly with the rise of GLP-1 receptor agonists and novel combination treatments.

Why Australia and New Zealand?

A biotech sponsor with operations in China and the United States launched a Phase II obesity clinical trial across Australia and New Zealand to evaluate a once-weekly GLP-1 analogue therapy. These countries were selected for their efficient regulatory frameworks, high-quality sites, and engaged patient populations, making them ideal locations for early-phase obesity studies that can support global submissions.

Novotech’s Expertise and Role

Chosen as the full-service CRO partner, Novotech leveraged its deep therapeutic expertise in obesity and metabolic diseases to deliver speed, quality, and consistency. Support included:

  • Regional project management
  • Site feasibility and selection
  • Medical monitoring
  • Data management and medical writing
  • Full-service trial operations across 9 sites (5 in Australia, 4 in New Zealand)

Recruitment began in December 2021.

Trial Outcomes

  • 206 patients enrolled (167 in Australia, 39 in New Zealand)
  • Recruitment period: Dec 2021 – Feb 2023
  • Average recruitment rate: ~35 patients per site, per month
  • Enrollment in Australia was so strong it was temporarily paused to allow New Zealand sites to catch up

Key Insights

This program highlights the operational advantages of conducting obesity trials in Australia and New Zealand:

  • Fast patient enrollment
  • Responsive regulatory environment
  • Strong investigator engagement
  • Efficient site activation across both countries

Novotech’s in-region teams ensured seamless coordination, consistent trial quality, and delivery against aggressive timelines.

Executive Summary

Novotech enabled a U.S.–China biotech sponsor to accelerate Phase II obesity trial execution across Australia and New Zealand, achieving rapid enrollment and high-quality data ahead of schedule. As the market for obesity therapeutics expands, Novotech’s proven expertise and regional presence make ANZ a strategic choice for sponsors seeking early-phase results that meet global regulatory standards.